ArticleMedical science monitor : international medical journal of experimental and clinical research2024
Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Estimation of Cardiovascular Risk Using SCORE2, REGICOR and Vascular Age Scales in Spanish Healthcare Workers: A Retrospective Longitudinal Study.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Non-functioning adrenal adenomas (NFA) are prevalent tumors often associated with metabolic disturbances compared to the general population. This study aimed to evaluate cardiovascular disease (CVD) risk in 106 patients with NFA using SCORE2 and SCORE2-OP algorithms. MATERIAL AND METHODS The study sample comprised of 106 patients with NFA. CVD risk was assessed using SCORE2 and SCORE2-OP charts. The study population was divided across different categories: low-to-moderate risk, high-risk, very high-risk of CVD. Anthropometric measurements, metabolic indices, lipid profiles, and carbohydrate metabolism parameters were analyzed across different CVD risk groups. RESULTS Very high-risk patients had a higher waist-to-hip ratio (WHR) value (0.95; 0.89-0.98) compared to low-to-moderate risk patients (0.89; 0.84-0.91; P=0.0049). Also, high-risk patients had a higher WHR value (0.92; 0.87-0.97) compared to low-to-moderate risk patients (0.89; 0.84-0.91; P=0.032). Patients with low-to-moderate CVD risk had significantly lower fasting glucose levels compared to patients with high CVD risk (5.35; 5.08-5.61 vs 5.78; 5.39-6.03; P=0.0093) as well as compared to patients with very high risk (5.35; 5.08-5.61 vs 5.83; 5.22-6.28; P=0.0230). There was no significant difference in lipid parameters and atherogenic indices between the groups based on CVD risk according to SCORE2 and SCORE2-OP. CONCLUSIONS Elevated fasting glucose levels are significantly associated with higher CVD risk in NFA patients, particularly in high and very high-risk group. Systolic blood pressure and WHR were identified as cost-effective measures for predicting of CVD among NFA patients. Metabolic indices did not show any significant differences across CVD risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.